A natural rise in estrogen levels should be expected in the days leading up to ovulation until the egg is ultimately released.
Fertility doctors may even administer extra estrogen using a patch or fertility medications for support of endometrial development prior to the transfer of embryos to the uterus.
Estrogen may be introduced later in the cycle.
With a rise in estrogen levels during this treatment, some patients may begin to experience certain symptoms.
Ovarian hyperstimulation syndrome, otherwise known as OHSS, is a potentially serious complication of in vitro fertilization that may be considered mild, moderate or severe depending on the symptoms associated with it.
Symptoms may begin about four to five days after the eggs are collected and many women may experience mild or moderate form of this syndrome, but this typically resolves on its own after a few days unless pregnancy occurs, in which case recovery may be delayed.
Possible symptoms of this syndrome may include pain, bloated feeling and mild abdominal swelling.
Ovarian cysts may be present in some women and fluid may collect in the abdominal cavity of some women, which may cause discomfort.
In rare cases in which the syndrome is severe, the ovaries may become very swollen and the woman may begin to feel nauseous and may experience vomiting and abdominal pain.
A reduction in the amount of urine produced may also be present, as well as shortness of breath.
Hospital admission is urgent in these cases.
This condition may be caused by an over response to fertility drugs administered during fertility treatment.
Those who may be most at risk of developing this syndrome include women with polycystic ovarian syndrome (PCOS), those with high estrogen hormone levels or large numbers of follicles or eggs, women who undergo administration of GnRh angonist, the use of hCG for luteal phase support or young women who are thin.
If you experience severe symptoms, it is advisable to seek medical care at a hospital right away, but for those with mild to moderate symptoms, consulting their doctor may be effective in determining the proper course of action.
If blood estrogen levels or ultrasound scans indicate that the patient may be at high risk of severe OHHS, withholding hCG administration may be recommended.
Women may react differently to fertility drugs, and some women may choose not to use fertility drugs when undergoing IVF or other fertility treatments and procedures.
Fertility doctors may even administer extra estrogen using a patch or fertility medications for support of endometrial development prior to the transfer of embryos to the uterus.
Estrogen may be introduced later in the cycle.
With a rise in estrogen levels during this treatment, some patients may begin to experience certain symptoms.
Ovarian hyperstimulation syndrome, otherwise known as OHSS, is a potentially serious complication of in vitro fertilization that may be considered mild, moderate or severe depending on the symptoms associated with it.
Symptoms may begin about four to five days after the eggs are collected and many women may experience mild or moderate form of this syndrome, but this typically resolves on its own after a few days unless pregnancy occurs, in which case recovery may be delayed.
Possible symptoms of this syndrome may include pain, bloated feeling and mild abdominal swelling.
Ovarian cysts may be present in some women and fluid may collect in the abdominal cavity of some women, which may cause discomfort.
In rare cases in which the syndrome is severe, the ovaries may become very swollen and the woman may begin to feel nauseous and may experience vomiting and abdominal pain.
A reduction in the amount of urine produced may also be present, as well as shortness of breath.
Hospital admission is urgent in these cases.
This condition may be caused by an over response to fertility drugs administered during fertility treatment.
Those who may be most at risk of developing this syndrome include women with polycystic ovarian syndrome (PCOS), those with high estrogen hormone levels or large numbers of follicles or eggs, women who undergo administration of GnRh angonist, the use of hCG for luteal phase support or young women who are thin.
If you experience severe symptoms, it is advisable to seek medical care at a hospital right away, but for those with mild to moderate symptoms, consulting their doctor may be effective in determining the proper course of action.
If blood estrogen levels or ultrasound scans indicate that the patient may be at high risk of severe OHHS, withholding hCG administration may be recommended.
Women may react differently to fertility drugs, and some women may choose not to use fertility drugs when undergoing IVF or other fertility treatments and procedures.